Ranitidine Brand Names - Important Update
Ranitidine has been withdrawn from the market worldwide due to contamination with NDMA (a probable carcinogen), and no brand name formulation should be prescribed or used. The FDA requested withdrawal of all ranitidine products from the U.S. market in April 2020.
Critical Context
While the evidence provided discusses ranitidine formulations including:
- Zantac (the original brand name) - available as tablets, syrup, and effervescent tablets (EFFERdose)
- Ranitidine bismuth citrate (GR122311X) - a combination formulation
None of these products are currently available or recommended for use.
Historical Information (For Reference Only)
Prior to market withdrawal, the available ranitidine formulations included:
Oral Formulations
- Zantac tablets: 150 mg and 300 mg 1
- Zantac syrup: Peppermint-flavored, 15 mg/mL 2, 3
- Zantac EFFERdose: Citrus-flavored 25 mg effervescent tablets 3
Pediatric Preference Data
Research showed that 71% of children aged 4-8 years preferred the taste of effervescent tablets over syrup 3, which had implications for compliance in pediatric GERD management 2.
Current Alternatives
Patients previously on ranitidine should be transitioned to alternative H2-receptor antagonists or proton pump inhibitors:
H2-Receptor Antagonists (Alternative Options)
- Famotidine (Pepcid): 20 mg twice daily - equivalent to ranitidine 150 mg twice daily 4
- Nizatidine: 150 mg twice daily 4
- Cimetidine: 300 mg three-four times daily 4
Proton Pump Inhibitors (Often More Effective)
PPIs have demonstrated superior efficacy to H2-receptor antagonists for GERD and related conditions 2, 5.
The question about "best brand name for ranitidine" is no longer clinically relevant - the medication should not be used, and patients require alternative therapy.